Schwaber Mitchell J, Klarfeld-Lidji Shiri, Navon-Venezia Shiri, Schwartz David, Leavitt Azita, Carmeli Yehuda
Division of Epidemiology and Preventive Medicine, Tel Aviv Sourasky Medical Center, 6 Weizmann St., Tel Aviv 64239, Israel.
Antimicrob Agents Chemother. 2008 Mar;52(3):1028-33. doi: 10.1128/AAC.01020-07. Epub 2007 Dec 17.
Carbapenem-resistant Klebsiella pneumoniae (CRKP) is an emerging nosocomial pathogen. Little is known about its risk factors or mortality. We performed a case-case-control study to assess the risks for CRKP isolation and a retrospective cohort study to assess mortality in three groups of hospitalized adults: (i) patients from whom CRKP was isolated, (ii) patients from whom carbapenem-susceptible Klebsiella spp. (CSKS) were isolated, and (iii) controls from whom no Klebsiella spp. were isolated. After adjustment for length of stay (LOS), the demographics, comorbidities, and exposures of each case group were compared with those of the controls. Significant covariates were incorporated into LOS-adjusted multivariable models. In the mortality study, we evaluated the effect of CRKP on in-hospital death. There were 48 patients with CRKP isolation (21 died [44%]), 56 patients with CSKS isolation (7 died [12.5%]), and 59 controls (1 died [2%]). Independent risk factors for CRKP isolation were poor functional status (odds ratio [OR], 15.4; 95% confidence interval [CI], 4.0 to 58.6; P < 0.001); intensive care unit (ICU) stay (OR, 17.4; 95% CI, 1.5 to 201.9; P = 0.02); and receipt of antibiotics (OR, 4.4; 95% CI, 1.0 to 19.2; P = 0.05), particularly fluoroquinolones (OR, 7.2; 95% CI, 1.1 to 49.4; P = 0.04). CRKP was independently associated with death when patients with CRKP were compared with patients with CSKS (OR, 5.4; 95% CI, 1.7 to 17.1; P = 0.005) and with controls (OR, 6.7; 95% CI, 2.4 to 18.8; P < 0.001). After adjustment for the severity of illness, CRKP isolation remained predictive of death, albeit with a lower OR (for the CRKP group versus the CSKS group, OR, 3.9; 95% CI, 1.1 to 13.6; and P = 0.03; for the CRKP group versus the controls, OR, 5.0; 95% CI, 1.7 to 14.8; and P = 0.004). CRKP affects patients with poor functional status, an ICU stay, and antibiotic exposure and is an independent predictor of death.
耐碳青霉烯类肺炎克雷伯菌(CRKP)是一种新出现的医院病原体。对其危险因素或死亡率了解甚少。我们进行了一项病例-病例对照研究以评估分离出CRKP的风险,并进行了一项回顾性队列研究以评估三组住院成人的死亡率:(i)分离出CRKP的患者,(ii)分离出对碳青霉烯敏感的克雷伯菌属(CSKS)的患者,以及(iii)未分离出克雷伯菌属的对照。在调整住院时间(LOS)后,将每个病例组的人口统计学、合并症和暴露情况与对照组进行比较。将显著的协变量纳入LOS调整后的多变量模型。在死亡率研究中,我们评估了CRKP对住院死亡的影响。有48例患者分离出CRKP(21例死亡[44%]),56例患者分离出CSKS(7例死亡[12.5%]),59例对照(1例死亡[2%])。分离出CRKP的独立危险因素是功能状态差(比值比[OR],15.4;95%置信区间[CI],4.0至58.6;P<0.001);入住重症监护病房(ICU)(OR,17.4;95%CI,1.5至201.9;P = 0.02);以及接受抗生素治疗(OR,4.4;95%CI,1.0至19.2;P = 0.05),特别是氟喹诺酮类(OR,7.2;95%CI,1.1至49.4;P = 0.04)。当将CRKP患者与CSKS患者进行比较时,CRKP与死亡独立相关(OR,5.4;95%CI,1.7至17.1;P = 0.005),与对照相比也是如此(OR,6.7;95%CI,2.4至18.8;P<0.001)。在调整疾病严重程度后,CRKP分离仍可预测死亡,尽管OR较低(CRKP组与CSKS组相比,OR,3.9;95%CI,1.1至13.6;P = 0.03;CRKP组与对照组相比,OR,5.0;95%CI,1.7至14.8;P = 0.004)。CRKP影响功能状态差、入住ICU和接受抗生素治疗的患者,并且是死亡的独立预测因素。